

**March 27, 2024**

**BSE Limited**

Department of Corporate Relationship  
1<sup>st</sup> Floor, New Trade Ring, Rotunda Building  
Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai- 400001  
*Scrip Code: 524742*

**National Stock Exchange of India Ltd**

Department of Corporate Services  
Exchange Plaza, 5<sup>th</sup> Floor,  
C-1, Block G, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
*Scrip Code: CAPLIPOINT.*

Dear Sir/Madam,

**Sub: Press Release – Commencement of Operations by Caplin One Labs Limited**

Attaching herewith a Press Release regarding completion of state-of-the-art Oncology facility at Kakkalur, near Chennai, and commencement of operations by Caplin One Labs Limited (Formerly Known as Caplin Onco Limited), the wholly-owned subsidiary of the company. Request you to take the same on record.

Thanking You,

Sincerely Yours  
**For Caplin Point Laboratories Limited**

**Venkatram G**  
**General Counsel & Company Secretary**  
**Membership No. A23989**  
**Encl: A/a**

## Caplin Group successfully completes new Oncology (anti-cancer) facility, commences operations

**Chennai, March 27, 2024:** Caplin One Labs Limited, a wholly owned subsidiary of Caplin Point Laboratories Limited, is pleased to announce the completion of its state-of-the-art Oncology facility at Kakkalur, near Chennai, and immediate commencement of operations. The total investment commitment for this facility is Rs. 150 Crores, funded entirely from internal accruals. To start with, the unit will focus on manufacturing a range of Oral Solid Dosage Oncology products, with the Injectable division to commence operations in the next few months. The company plans to expand the portfolio to over 50 oncology products progressively.

The facility will manufacture tablets (both coated & uncoated), capsules, and injections, catering to the growing demand for high-quality pharmaceuticals in the oncology segment. Initially, these oncology products will be targeted at Latin American countries, leveraging Caplin Group's established presence in these markets. In the medium term, Caplin One Labs Limited aims to launch these oncology products in regulated markets such as the US, EU, Mexico, and others.

The facility's compliance with US FDA standards from the outset is expected to streamline the approval process, ensuring swift market entry and availability of these critical treatments to patients worldwide. Caplin Group remains dedicated to advancing healthcare solutions, improving patient outcomes, and making a positive impact on communities globally.

### Commenting on the achievement, Mr. C.C. Paarthipan, Chairman said:

*"We are pleased to announce the commencement of operations at our Oncology facility located in Kakkalur. We are committed to delivering superior pharmaceutical products and increasing our market footprint. Caplin has started offering a comprehensive array of oncology solutions to address unmet medical needs, reflecting its dedication to healthcare innovation. Our focus on innovation and technology along with regulatory compliance, well positions us for the long-term success. Our vision is to continue investing judiciously in the oncology business which has significant social impact."*

### About Caplin Point Laboratories Limited

Caplin Point Laboratories Limited is a fast-growing pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. The Company has state of the art manufacturing facilities that cater to a complete range of finished dosage forms. Caplin Point is one of the few companies to show consistent high-quality growth in cashflows, Profitability and Revenues over the last 15 years.

Caplin Point has appeared on Forbes “Asia’s 200 Best Under a Billion” list for an unprecedented 6<sup>th</sup> time in the last 10 years and was awarded “The Emerging Company of 2018” and “Business Excellence Award for 2019” by Economic Times.

**CAUTIONARY STATEMENT:**

*This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward-looking statements. No warranties or representations are made as to the accuracy, achievement or reasonableness of such statements, estimates or projections, and Caplin Point has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.*

**For details, please contact:**

<p><b>Investor Relations at Caplin</b>            Mr G Venkatram            (General Counsel &amp; Company Secretary)            Tel: +91 44 24968000  <a href="mailto:investor@caplinpoint.net">investor@caplinpoint.net</a></p> <p><b>Churchgate Partners</b>            Paresh Rohra / Rajiv Pandya            Churchgate Partners            +91 22 6169 5988  <a href="mailto:caplinpoint@churchgatepartners.com">caplinpoint@churchgatepartners.com</a></p>	<p><b>Registered Office</b>            Caplin Point Laboratories Limited            3<sup>rd</sup> Floor, Ashvich Tower, No. 3, Developed            Plots Industrial Estate, Perungudi,            Chennai – 600 096, Tamil Nadu, India.            Tel: +91 44 2496 8000            CIN: L24231TN1990PLC019053            ISIN: INE475E01026            NSE Code: CAPLIPOINT            BSE CODE: 524742            Website: <a href="http://www.caplinpoint.net">www.caplinpoint.net</a></p>
---	---